CEO Peter Blume-Jensen was paid $2,718,538 in fiscal year 2025, ↑ up 35.9% from fiscal year 2024 (SEC filing 0001193125-26-194206 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,718,538 ↑ Peter Blume-Jensen total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ACRV's next annual pay disclosure, estimated May 5, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Peter Blume-Jensen | $709,893 | $0 | $0 | $1,592,245 | $410,400 | $0 | $6,000 | $2,718,538 |
| Chief Executive Officer, President and Director | ||||||||
| Kristina Masson | 594,472 | 0 | 0 | 573,206 | 251,248 | 0 | 6,000 | 1,424,926 |
| Executive Vice President, Business Operations, Director | ||||||||
| Eric Devroe | 528,745 | 0 | 0 | 573,206 | 250,052 | 0 | 6,000 | 1,358,003 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Peter Blume-Jensen | $2,718,538 | $2,000,312 | $6,465,973 | ↑ +718,226 |
| Kristina Masson | 1,424,926 | 1,197,176 | 739,783 | ↑ +227,750 |
| Eric Devroe | 1,358,003 | 1,146,728 | — | ↑ +211,275 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Acrivon Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ACRV reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name ACRV as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Charles Baum, M.D., Ph.D | Independent Director | $77,870 |
| Derek DiRocco, Ph.D | Independent Director | $70,370 |
| Ivana Magovčević-Liebisch, Ph.D., J.D | Independent Director | $65,370 |
| Michael Tomsicek, M.B.A | Independent Director | $72,870 |
| Santhosh Palani, Ph.D., CFA | Independent Director | $118,308 |
| Sharon Shacham, Ph.D., M.B.A | Independent Director | $65,370 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Erick Gamelin | Chief Development Officer | 2026-05-14 | D | 404 | $2 | $776 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-14 | D | 490 | 2 | 941 | Common, indirect | Form 4 ↗ |
| Katharine Peterson | Chief Accounting Officer | 2026-05-14 | D | 99 | 2 | 190 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-14 | D | 1,253 | 2 | 2,406 | Common, indirect | Form 4 ↗ |
| Eric Devroe | Chief Operating Officer | 2026-05-14 | D | 613 | 2 | 1,177 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-05-14 | D | 184 | 2 | 353 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-18 | A | 72,706 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Adam D. Levy | Chief Financial Officer | 2026-05-18 | A | 46,167 | 0 | 0 | Common | Form 4 ↗ |
| Derek DiRocco | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common, indirect | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-05-18 | A | 9,366 | 0 | 0 | RSU | Form 4 ↗ |
| Erick Gamelin | Chief Development Officer | 2026-05-18 | A | 38,584 | 0 | 0 | Common | Form 4 ↗ |
| Ivana Magovcevic-Liebisch | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Santhosh Palani | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-18 | A | 180,095 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Mansoor Raza Mirza | Chief Medical Officer | 2026-05-18 | A | 38,817 | 0 | 0 | Common | Form 4 ↗ |
| Sharon Shacham | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Charles M. Baum | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Katharine Peterson | Chief Accounting Officer | 2026-05-18 | A | 14,227 | 0 | 0 | Common | Form 4 ↗ |
| Michael John Tomsicek | Director | 2026-05-18 | A | 9,366 | 0 | 0 | Common | Form 4 ↗ |
| Eric Devroe | Chief Operating Officer | 2026-05-18 | A | 72,981 | 0 | 0 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-05-18 | A | 49,830 | 0 | 0 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-05-21 | D | 13,729 | 2 | 24,575 | Common, indirect | Form 4 ↗ |
| Charles M. Baum | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ivana Magovcevic-Liebisch | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Shacham | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael John Tomsicek | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Santhosh Palani | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derek DiRocco | Director | 2026-06-17 | A | 20,275 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-07-21 | D | 573 | 2 | 1,008 | Common | Form 4 ↗ |
| Adam D. Levy | Chief Financial Officer | 2026-08-04 | D | 1,142 | 2 | 1,793 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-08-18 | D | 484 | 2 | 973 | Common, indirect | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-08-18 | D | 1,229 | 2 | 2,470 | Common, indirect | Form 4 ↗ |
| Eric Devroe | Chief Operating Officer | 2026-08-18 | D | 604 | 2 | 1,214 | Common | Form 4 ↗ |
| Erick Gamelin | Chief Development Officer | 2026-08-18 | D | 400 | 2 | 804 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-08-18 | D | 185 | 2 | 372 | Common | Form 4 ↗ |
| Katharine Peterson | Chief Accounting Officer | 2026-08-18 | D | 101 | 2 | 203 | Common | Form 4 ↗ |
| Peter Blume-Jensen | Director | 2026-08-25 | D | 14,036 | 2 | 30,969 | Common, indirect | Form 4 ↗ |
| Michaela Levin | Chief Business Officer | 2026-08-31 | A | 130,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michaela Levin | Chief Business Officer | 2026-08-31 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Mary Miller | Chief Legal Officer | 2026-10-05 | D | 294 | 2 | 585 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kristina Masson | OPTION | — | — | — | — | — | $573,206 |
| Peter Blume-Jensen | OPTION | — | — | — | — | — | 1,592,245 |
| Eric Devroe | OPTION | — | — | — | — | — | 573,206 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kristina Masson | $0 | $0 | $573,206 | 0.0% |
| Peter Blume-Jensen | 0 | 0 | 1,592,245 | 0.0% |
| Eric Devroe | 0 | 0 | 573,206 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Peter Blume-Jensen | RSU | 123,499 | — | $297,633 |
| Peter Blume-Jensen | RSU | 98,536 | — | 126,690 |
| Kristina Masson | RSU | 39,414 | — | 50,676 |
| Eric Devroe | RSU | 39,414 | — | 50,676 |
| Peter Blume-Jensen | RSU | 15,023 | — | 36,205 |
| Eric Devroe | RSU | 8,346 | — | 20,114 |
| Kristina Masson | RSU | 6,677 | — | 16,092 |
| Peter Blume-Jensen | Option | 390,390 | 5.31 | — |
| Kristina Masson | Option | 140,540 | 5.31 | — |
| Eric Devroe | Option | 140,540 | 5.31 | — |
Our current executive compensation program is intended to align executive compensation with our business objectives and to enable us to attract, retain and reward executive officers who contribute to our long-term success.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | — | — | — | — | — |
| 2025 | 2025-06-13 | — | — | — | — | — |
| 2024 | 2024-06-20 | — | — | — | — | — |
| 2023 | 2023-06-22 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-17 | —a |
| 2025 | 2025-06-13 | —b |
| 2024 | 2024-06-20 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Santhosh Palani, Ph.D., CFAIndependent · Compensation · Nominating/Governance (Chair) | $57,500 | — | $17,870 | — | $42,938 | $118,308 |
| Charles Baum, M.D., Ph.DIndependent · Compensation (Chair) · Nominating/Governance | 60,000 | — | 17,870 | — | 0 | 77,870 |
| Michael Tomsicek, M.B.AIndependent · Audit (Chair) | 55,000 | — | 17,870 | — | 0 | 72,870 |
| Derek DiRocco, Ph.DIndependent · Audit · Nominating/Governance | 52,500 | — | 17,870 | — | 0 | 70,370 |
| Sharon Shacham, Ph.D., M.B.AIndependent · Compensation | 47,500 | — | 17,870 | — | 0 | 65,370 |
| Ivana Magovčević-Liebisch, Ph.D., J.DIndependent · Audit | 47,500 | 0 | 17,870 | 0 | 0 | 65,370 |
| Kristina Masson, Ph.D., M.B.AEmployee director | — | — | — | — | — | 0 |
| Peter Blume-Jensen, M.D., Ph.DEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $210,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $320,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $42,938 |
| Total cost of the board | $362,938 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Acrivon Therapeutics | 2025 | Peter Blume-Jensen | $709,893 | $0 | $1,592,245 | $410,400 | $2,718,538 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Peter Blume-Jensen | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Executive Compensation”. As printed: 2,718,538. Filing ↗machine: r3 · c24 · span 492621–492630 |
| 2 | Section 01, Kristina Masson | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Executive Compensation”. As printed: 1,424,926. Filing ↗machine: r5 · c24 · span 511377–511386 |
| 3 | Section 01, Eric Devroe | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Executive Compensation”. As printed: 1,358,003. Filing ↗machine: r7 · c24 · span 530126–530135 |
| 4 | Section 03, Kristina Masson OPTION | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “THE CLASSDIRECTOR NOMINEES LISTED BELOW. &” · grants of plan-based awards table. Filing ↗machine: t20 · r5 · c12 · span 507242–507249 |
| 5 | Section 03, Peter Blume-Jensen OPTION | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “THE CLASSDIRECTOR NOMINEES LISTED BELOW. &” · grants of plan-based awards table. Filing ↗machine: t20 · r3 · c12 · span 488484–488493 |
| 6 | Section 03, Eric Devroe OPTION | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “THE CLASSDIRECTOR NOMINEES LISTED BELOW. &” · grants of plan-based awards table. Filing ↗machine: t20 · r7 · c12 · span 525991–525998 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-19 | 0001193125-26-115123 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Santhosh Palani, Ph.D., CFA | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 118,308. Filing ↗machine: span 388578–388787 |
| 9 | Section 08, Charles Baum, M.D., Ph.D | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 77,870. Filing ↗machine: span 378977–379185 |
| 10 | Section 08, Michael Tomsicek, M.B.A | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 72,870. Filing ↗machine: span 394965–395173 |
| 11 | Section 08, Derek DiRocco, Ph.D | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 70,370. Filing ↗machine: span 382164–382372 |
| 12 | Section 08, Sharon Shacham, Ph.D., M.B.A | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 65,370. Filing ↗machine: span 391775–391983 |
| 13 | Section 08, Ivana Magovčević-Liebisch, Ph.D., J.D | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 65,370. Filing ↗machine: span 385379–385587 |
| 14 | Section 08, Kristina Masson, Ph.D., M.B.A | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 08, Peter Blume-Jensen, M.D., Ph.D | DEF 14A | 2026-04-30 | 0001193125-26-194206 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 02, Erick Gamelin 2026-05-14 | Form 4 | 2026-05-18 | 0000905148-26-002500 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Peter Blume-Jensen 2026-05-14 | Form 4 | 2026-05-18 | 0000905148-26-002498 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Katharine Peterson 2026-05-14 | Form 4 | 2026-05-18 | 0000905148-26-002502 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Peter Blume-Jensen 2026-05-14 | Form 4 | 2026-05-18 | 0000905148-26-002498 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Eric Devroe 2026-05-14 | Form 4 | 2026-05-18 | 0000905148-26-002499 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Mary Miller 2026-05-14 | Form 4 | 2026-05-18 | 0000905148-26-002501 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Peter Blume-Jensen 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002549 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Adam D. Levy 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002552 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Derek DiRocco 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002558 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-05-18 | Form 4 | 2026-05-20 | 0001231919-26-000517 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Erick Gamelin 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002551 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Ivana Magovcevic-Liebisch 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002559 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Santhosh Palani 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002560 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Peter Blume-Jensen 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002549 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Mansoor Raza Mirza 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002555 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Sharon Shacham 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002562 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Charles M. Baum 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002557 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Katharine Peterson 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002556 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Michael John Tomsicek 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002563 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Eric Devroe 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002550 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Mary Miller 2026-05-18 | Form 4 | 2026-05-20 | 0000905148-26-002553 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Peter Blume-Jensen 2026-05-21 | Form 4 | 2026-05-26 | 0000905148-26-002652 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Charles M. Baum 2026-06-17 | Form 4 | 2026-06-22 | 0000905148-26-003024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-06-17 | Form 4 | 2026-06-22 | 0001231919-26-000686 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Ivana Magovcevic-Liebisch 2026-06-17 | Form 4 | 2026-06-22 | 0000905148-26-003034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Sharon Shacham 2026-06-17 | Form 4 | 2026-06-22 | 0000905148-26-003041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Michael John Tomsicek 2026-06-17 | Form 4 | 2026-06-22 | 0000905148-26-003042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Santhosh Palani 2026-06-17 | Form 4 | 2026-06-22 | 0000905148-26-003035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Derek DiRocco 2026-06-17 | Form 4 | 2026-06-22 | 0000905148-26-003033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Mary Miller 2026-07-21 | Form 4 | 2026-07-23 | 0000905148-26-003334 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Adam D. Levy 2026-08-04 | Form 4 | 2026-08-06 | 0000905148-26-003499 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Peter Blume-Jensen 2026-08-18 | Form 4 | 2026-08-20 | 0000905148-26-003836 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Peter Blume-Jensen 2026-08-18 | Form 4 | 2026-08-20 | 0000905148-26-003836 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Eric Devroe 2026-08-18 | Form 4 | 2026-08-20 | 0000905148-26-003837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Erick Gamelin 2026-08-18 | Form 4 | 2026-08-20 | 0000905148-26-003838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Mary Miller 2026-08-18 | Form 4 | 2026-08-20 | 0000905148-26-003839 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Katharine Peterson 2026-08-18 | Form 4 | 2026-08-20 | 0000905148-26-003840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Peter Blume-Jensen 2026-08-25 | Form 4 | 2026-08-27 | 0000905148-26-003968 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michaela Levin 2026-08-31 | Form 4 | 2026-09-02 | 0000905148-26-004065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Michaela Levin 2026-08-31 | Form 4 | 2026-09-02 | 0000905148-26-004065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Mary Miller 2026-10-05 | Form 4 | 2026-10-07 | 0000905148-26-004399 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 06, 2026 vote | Form 8-K | 2026-06-17 | 0001193125-26-274410 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 58 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0000950170-25-086246 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 59 | Section 06, 2024 vote | Form 8-K | 2024-06-21 | 0000950170-24-075760 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 60 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 61 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 62 | Section 09b board cost (computed) | Computed | — | — | Cash 320,000 + equity 0 + all other 42,938 = 362,938, summed across the director compensation table rows.machine: formula: Σ = 362,938 |
| 63 | Acrivon Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-194206 | CEO total compensation as printed in Acrivon Therapeutics's own proxy. As printed: 2,718,538. Filing ↗machine: r3 · c24 · span 492621–492630 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.